Ocugen Q4 Earnings Call Highlights

Core Insights - Ocugen is advancing its gene therapy pipeline, particularly focusing on OCU400 for retinitis pigmentosa (RP) and OCU410 for Stargardt disease, with significant milestones expected in the coming years [1][2][3][4]. Group 1: OCU400 Development - The Phase III liMeliGhT trial for OCU400 has completed enrollment with 140 patients, and top-line data is anticipated in Q1 2027, which is expected to support a biologics license application (BLA) filing and potential approval in 2027 [1][8]. - OCU400 is designed as a modifier gene therapy targeting multiple mutations in RP, potentially addressing 98% to 99% of RP patients, compared to the only approved therapy that targets only 1% to 2% of patients [2][3]. Group 2: Financial Performance - In 2025, research and development expenses rose to $39.8 million, with a net loss of $0.23 per share, compared to $32.1 million and $0.20 per share in 2024 [6][28]. - The company has extended its cash runway into late 2026, with potential extension into Q2 2027 if $30 million in warrants are exercised [6][24]. Group 3: Stargardt and Geographic Atrophy Programs - The GARDian3 trial for Stargardt disease is ahead of schedule, with top-line data expected in Q2 2027, and the European Medicines Agency has confirmed that data from a single U.S. trial can support a European filing [7][12][13]. - Preliminary Phase II data for OCU410 in geographic atrophy showed a 46% reduction in lesion growth at 12 months, with plans for Phase III initiation in 2026 [17][18]. Group 4: Business Development and Partnerships - Ocugen has executed its first regional licensing agreement with Kwangdong Pharmaceutical for exclusive rights to OCU400 in Korea, which includes upfront fees and royalties [22]. - The company has created a wholly owned subsidiary, Ocucelix, to focus on regenerative cell therapy assets, aiming to maximize value for shareholders [21]. Group 5: Upcoming Milestones - Key upcoming milestones include the completion of OCU410ST enrollment in early 2026, initiation of Phase III for OCU410, and the start of rolling BLA submission for OCU400 in Q3 2026 [25].